HNN3.0
Register
Register
Register

Project cooperationUpdated on 2 February 2026

Insulin and IGF Signalling Mechanisms in Metabolic, Cardiovascular and Cancer Diseases

group leader at IOCB Prague

Praha, Czech Republic

About

We investigate disease-relevant molecular mechanisms of insulin and insulin-like growth factor (IGF1/2) signalling, focusing on receptor specificity, pathway selectivity and dysregulation in metabolic, cardiovascular and cancer-related conditions.

Using synthetic insulin and IGF analogues, peptide mimetics and receptor-selective tools, we dissect metabolic versus mitogenic signalling and their contribution to disease phenotypes. Our work addresses fundamental mechanisms underlying insulin resistance, altered growth signalling and hormone-driven disease progression.

We seek to contribute as a scientific partner to Horizon Europe Health projects focused on disease mechanisms, biomarkers and targeted therapeutic strategies, including topics related to cardiovascular diseases, metabolic disorders and cancer.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

Type

  • Partner seeks Consortium/Coordinator

Organisation

IOCB Prague

R&D Institution

Prague, Czech Republic

Similar opportunities

  • Project cooperation

    Insulin and IGF Analogues for Targeted Modulation of Metabolic and Mitogenic Signalling

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Jiri Jiracek

    group leader at IOCB Prague

    Praha, Czech Republic

  • Project cooperation

    Preclinical R&D services

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Andras Nogradi

    Business Development Director at Pharmahungary Group

    Budapest, Hungary

  • Project cooperation

    Connected medical devices and real-world data to support sex and gender-specific cardiovascular research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Celia Bengougam

    Medical Affairs Team Leader at Withings

    Paris, France